**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 56233

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Prolonged prothrombin time at admission predicts poor clinical outcome in COVID-19 patients**

Wang L *et al.* Prolonged prothrombin time predict poor clinical outcome

Lang Wang, Wen-Bo He, Xiao-Mei Yu, Da-Long Hu, Hong Jiang

**Lang Wang, Wen-Bo He, Xiao-Mei Yu, Hong Jiang,** Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China

**Lang Wang, Wen-Bo He, Xiao-Mei Yu, Hong Jiang,** Cardiovascular Research Institute, Wuhan University, Wuhan 430060, Hubei Province, China

**Lang Wang, Wen-Bo He, Xiao-Mei Yu, Hong Jiang,** Hubei Key Laboratory of Cardiology, Wuhan 430060, Hubei Province, China

**Da-Long Hu,** Department of School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney 2052, Australia

**Author contributions:** Wang L and He WB drafted the manuscript; Jiang H and Wang L conceived the idea; Wang L, He WB and Yu XM reviewed the medical records and collected the data; Hu DL performed the statistical analysis and reviewed the manuscript; Jiang H reviewed the manuscript; All authors have read and approved the final manuscript.

**Supported by** the National Natural Science Foundation of China, No. 81570450 and No. 81900455.

**Corresponding author: Hong Jiang, MD, Chief Physician, Director, Full Professor,** Department of Cardiology, Renmin Hospital of Wuhan University, No. 238 Jiefang Road, District of Wuchang, Wuhan 430060, Hubei Province, China. hong-jiang@whu.edu.cn

**Received:** April 28, 2020

**Revised:** June 2, 2020

**Accepted:** September 8, 2020

**Published online:**

**Abstract**

BACKGROUND

The prognostic value of coagulation disorder in coronavirus disease 2019 (COVID-19) patients should be demonstrated.

AIM

To investigate the abnormalities of coagulation parameters in the patients with COVID-19 and their prognostic values.

METHODS

Consecutive patients admitted in the isolation ward of Renmin Hospital of Wuhan University from January 31 to February 5, 2020 with confirmed COVID-19 were included. The primary outcomes were death and survival as of March 11. Demographics, vital signs, comorbidities and laboratory tests were collected and compared between those who died and survivors. Logistic regression analysis for prognostic factors was performed. Kaplan-Meier analysis was used to compare the estimated survival rate between patients with prolonged prothrombin time and normal prothrombin time.

RESULTS

The total number of patients with confirmed COVID-19 who were enrolled was 213. The median age was 62 years, and 95 patients (44.6%) were men. Fifty-one patients were critical (23.9%), 79 patients were severe (37.1%) and 83 patients were moderate (39%). As of March 11, 2020, 99 patients were discharged (46.5%), 79 patients (37.1%) stayed in the hospital and 35 patients (16.2%) died. Median time to death was 6 (4-8) d, while median hospital stay was 32 (22-36) d in survivors (*P* < 0.001). More men (*P* = 0.002) and elderly patients (*P* < 0.001) were found in the group of those who died. The respiration rate at admission was higher in the group of those who died (*P* < 0.001). The incidences of hypertension (*P* = 0.028), cerebrovascular disease (*P* < 0.001), chronic kidney disease (*P* = 0.02) and chronic obstructive pulmonary disease (*P* < 0.001) were higher in the group of those who died. Platelet count was decreased in the group of those who died (*P* = 0.002) whereas prothrombin time (*P* < 0.001), activated partial thromboplastin time (*P* = 0.033), concentration of D-dimer (*P* < 0.001) and fibrin degradation products (*P* < 0.001) were increased in the group of those who died. Prothrombin time [odds ratio (OR): 2.19, *P* = 0.004], respiration rate (OR: 1.223, *P* < 0.001), age (OR: 1.074, *P* < 0.001) and fibrin degradation products concentration (OR: 1.02, *P* = 0.014) were predictors of death. The survival rate was significantly lower in patients with prolonged prothrombin time compare to those with normal prothrombin time (*P* < 0.001).

CONCLUSION

Prothrombin time, concentration of fibrin degradation products, respiration rate and age were predictive factors for clinical outcomes of COVID-19 patients.

**Key words:** COVID-19; Coagulation; Prothrombin time; Fibrin degradation products; Prognosis; Infectious disease

Wang L, He WB, Yu XM, Hu DL, Jiang H. Prolonged prothrombin time at admission predicts poor clinical outcome in COVID-19 patients. *World J Clin Cases* 2020; In press

**Core tip:** Coagulation disorders were significantly more common in the patients who died with coronavirus disease 2019 than the survivors. Prothrombin time (PT), concentration of fibrin degradation products, respiration rate and age were predictive factors for fatal outcome. The fatality of patients with prolonged PT at admission was significantly higher than those with normal PT. Patients with prolonged PT at admission should be paid more attention to and treated with caution.

**INTRODUCTION**

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Since the first COVID-19 case was diagnosed in December 2019, the SARS-CoV-2 has been spreading rapidly around the world. As of March 19, it has caused 209839 infection cases including 8778 deaths[1]. According to the preliminary statistics from the Chinese Center for Disease Control and Prevention, nearly 20% of the patients were severe to critical, and the case-facility rate of which was much higher than the whole patient population[2]. The disease progressed extremely fast in some severe to critical patients. Thus, early identification of COVID-19 patients at high risk is important for improving the clinical practice and outcomes.

Coagulation disorder has been reported in COVID-19 patients in several descriptive studies[3-5]. The elevation of D-dimer and fibrin degradation products (FDP), shortened or prolonged prothrombin time (PT), abnormal platelet count, occurrence of thrombosis or bleeding and complication of disseminated intravascular coagulation (DIC) were observed in COVID-19 patients in different clinical stages[6,7]. These findings indicate that the coagulation disorder played an important role in the clinical process of COVID-19. Coagulation disorder at the end-stage of COVID-19 or after invasive treatment is common and reasonable but with limited prognostic value. The coagulation function at the early stage of hospitalization should be paid more attention to, which may help the doctors to identify patients at high risk and guide the clinical strategy.

**MATERIALS AND METHODS**

***Study design and participants***

This is a retrospective, single-center study. Confirmed COVID-19 cases admitted from January 31 to February 5, 2020 to Renmin Hospital of Wuhan University were enrolled in this study. The patients with recent trauma, anticoagulation treatment, confirmed thrombosis or bleeding before hospitalization were excluded. The diagnosis of COVID-19 was based on the interim guidance for novel coronavirus pneumonia published by the National Health Commission of the People’s Republic of China[8]. Patients with COVID-19 were divided into mild, moderate and severe according to the report of the World Health Organization-China joint mission on COVID-19[9]. Laboratory confirmed cases without pneumonia were classified as mild, laboratory confirmed cases with pneumonia were classified as moderate, patients with dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, PaO2/FiO2 ratio < 300, and/or lung infiltrates in > 50% of the lung field within 24-48 h were classified as severe. The patients with respiratory failure requiring mechanical ventilation, shock or other organ failure that required intensive care were classified as critical. This study (WDRY2020-K032) was approved by the Ethics Committee of Renmin Hospital of Wuhan University.

***Procedures***

Specific nucleic acid of SARS-CoV-2 was detected using real-time polymerase chain reaction to confirm viral infection. Chest X-ray and/or computed tomography were performed for the COVID-19 diagnosis. The patients’ medical records were reviewed by trained physicians. Demographics, vital signs, comorbidities, laboratory results of platelet count and coagulation function were collected. All the vital signs were achieved at admission. Comorbidities including hypertension, diabetes, cardiovascular disease, cerebrovascular disease, chronic kidney disease, chronic obstructive pulmonary disease (COPD), malignancy and autoimmune diseases were collected from patient history. All the blood samples for laboratory tests were collected within 24 h after admission. Platelet count was determined using the Sysmex XN-9000 (Japan), an automated hematology analyzer. The PT, activated partial thromboplastin time (APTT) and thrombin time (TT) were determined by the clot formation technique. The concentration of fibrin, FDP and D-dimer were quantified by the nephelometric analysis. All the coagulation tests were performed using a Sysmex CS5100 automatic coagulation analyzer (Japan) and proprietary reagents. The normal ranges of the laboratory findings were according to the test manual and reagent description of Renmin Hospital of Wuhan University.

***Statistical analysis***

Basic statistical analyses were performed using Statistic Package for Social Science version 26.0 (Chicago, IL, United States). The normality of continuous variables was tested using the Kolmogorov-Smirnov test. Hypothesis testing was performed for comparing continuous and categorical variables in different outcome groups using the Mann-Whitney *U* test and chi-squared test, respectively. The comorbidities, clinical and laboratory variables that differed significantly based on comparative statistics were included in univariate and multivariate analysis. Variables with statistical significance in the univariate logistic regression were included in the multivariate analysis using forward stepwise logistic regression. The survival rates were analyzed using Kaplan-Meier analysis. All significance levels were computed for two-tailed testing and the cutoff of significance was set at *P* < 0.05 and high significance at *P* < 0.001.

**RESULTS**

***Outcomes***

The clinical outcomes were survival and death as of March 11, *i.e*. 5 wk after the last admission. According to the interim guidance for novel coronavirus pneumonia published by the National Health Commission of the People’s Republic of China[8], patients were discharged when their symptoms improved significantly, with no fever for at least 3 d, obvious absorption of inflammation on pulmonary imaging and negative results for at least two consecutive SARS-CoV-2 nucleic acid tests with an interval of more than 24 h. Patients who did not meet the discharge standard stayed at the hospital for treatment. The discharged patients and those who stayed in the hospital until the end date of follow-up were grouped in the survival group.

***Demographics and baseline clinical characteristics***

Of 213 patients enrolled, the median age was 62 years, and 95 were men (44.6%). As presented in Table 1, 61% of the enrolled patients were classified as severe or critical. All the patients who died were critically ill. By Mar 11, 2020, 99 patients were discharged (46.5%), 79 patients (37.1%) stayed in the hospital and 35 patients (16.2%) died. There were more males and elderly patients in the group of those who died. Compared with the survivors, comorbidities including hypertension, cerebrovascular disease, chronic kidney disease and COPD were more prevalent in the group of those who died. Vital signs at admission including heart rate, systolic blood pressure, diastolic blood pressure and respiration rate were compared between groups. The respiration rate was significantly higher in those who died.

The onset-to-admission time was compared between the survivors and those who died, and no significant difference was found. The length of hospital stay was also analyzed. For the patients who continued hospitalization until the end date of follow-up, the length of stay was defined as the duration from admission to the end date of follow-up. The length of hospital stay in survivors was 32 (22-36) d, while the admission-to-death time was only 6 (4-8) d for those who died.

***Laboratory findings***

Platelet count and coagulation parameters were analyzed in the present study. Of the included 213 patients, thrombocytopenia was found in 26 (12.2%), and thrombocytosis was found in 10 (4.7%). PT was prolonged in 39 patients (18.8%). Activated APTT was shortened in 27 patients (12.7%) and was prolonged in 56 patients (26.3%). Eight patients (3.8%) were found with prolonged TT. The shortening of PT or TT was not observed in the present study. The fibrinogen levels in 9 patients (4.7%) were below the normal range and were elevated in 105 patients (49.3%). The concentrations of D-dimer were increased in 123 patients (57.7%), and the concentrations of FDP were elevated in 66 patients (31%).

Comparison of platelet count, coagulation function parameters and the incidence of abnormalities in coagulation indices between survivors and those who died are shown in Table 2. The platelet count was significantly lower in those who died, whereas PT, APTT and the concentrations of D-dimer and FDP were all significantly higher in those who died. There were significant differences in the incidences of thrombocytopenia, PT prolongation, APTT prolongation, TT prolongation, fibrinogen reduction, D-dimer elevation and FDP elevation between those who survived and those who died.

***Univariate and multivariate analysis for the prognostic factors***

Univariate and multivariate logistic regressions were used to analyze the risk factors for fatal outcome (Table 3). The factors with significant differences between the death and survival groups, including age, sex, comorbidities, respiration rate, platelet count, PT, APTT, D-dimer and FDP, were included in the regression. Univariate analysis showed that age, sex, hypertension, cerebrovascular disease, chronic kidney disease, COPD, respiration rate, PT, concentrations of D-dimer and FDP may contribute to the death risk of COVID-19 patients. Then those factors with statistical significance in the univariate regression were taken for the multivariate analysis using forward stepwise logistic regression, in which PT [odds ratio (OR): 2.19, 95% confidence interval (CI): 1.285-3.733, *P* = 0.004], respiration rate (OR: 1.223, 95%CI: 1.095-1.366, *P* = 0.001), age (OR: 1.074, 95%CI: 1.034-1.115, *P* = 0.001) and FDP concentration (OR: 1.02, 95%CI: 1.004-1.037, *P* = 0.014) remained to be the significant predictors for death in the multivariate logistic model.

***Survival curves in patients with prolonged PT and normal PT***

The survival curves of patients with prolonged PT and normal PT were plotted, and the survival rates were analyzed using Kaplan-Meier analysis (Figure 1). The survival rate at day 5 of hospitalization in normal PT group and prolonged PT group were estimated at 95.8% ± 1.6% and 76.9% ± 6.7%, respectively. The survival rate at day 11 in normal PT group and prolonged PT group were estimated at 90.4% ± 2.3% and 64.1% ± 7.7%, respectively. According to the result of Log-rank, Breslow and Tarone-Ware tests, the survival curves of the two groups have a highly significant difference (*P* = 0.001).

**DISCUSSION**

In the present study, we investigated the prognostic value of coagulation parameters in patients with COVID-19 based on at least 5 wk of follow-up. Prolonged PT at admission was found to be a strong predictor for a poor outcome in COVID-19 patients as well as age, respiration rate and FDP concentration, which were also found to contribute to the risk of death in COVID-19 patients.

Renmin Hospital of Wuhan University is a designated hospital for severe COVID-19 patients. In the present study, 35 of 213 patients had died by the 5 wk follow-up, and the CRF was 16.4%, which was higher than the whole patient population. Up to 61% of the enrolled patients were severe to critical, which might contribute to the higher fatality rate. The median survival time for those who died was 6 d, indicating that the disease progressed rapidly in some critical patients. Elderly age and more males were more commonly found in the group of those who died, which was consistent with previous reports[2]. Comorbidities including hypertension, cerebrovascular disease, chronic kidney disease and COPD, which are more common in the elderly people, were more prevalent in the group of those who died in the present study. The median heart rate and blood pressure at admission were all in the normal range both in survivors and those who died, indicating the vital signs of most patients were stable at admission. The respiration rate was significantly higher in those who died. The increased respiration rate might reflect the severity of lung lesions and hypoxic conditions in COVID-19 patients.

Coagulation disorder has been reported in various viral infections including SARS-CoV, MERS-CoV and influenza virus infection[10-14]. All aspects of the coagulation cascade, primary hemostasis and fibrinolysis could be affected. The coagulation parameters not only reflect the hemostasis but also associate with the inflammation and organ dysfunction[15]. In the present study, the comparison of laboratory findings between those who died and survivors showed a significant difference in platelet count and coagulation parameters. Both thrombocytopenia and thrombocytosis were found in COVID-19 patients. However, platelet count in those who died was significantly lower than that in the survivors. The incidence of thrombocytopenia was correspondingly higher in those who died. Similar findings in platelet count had been reported in SARS-CoV infection[16]. Consumption associated with thrombin-mediated platelet activation and adhesion to endothelial cells and leucocytes could contribute to the reduction of circulating platelets in the critically ill patients[17].

No patients showed shortened PT, whereas prolonged PT was found in 18.8% of the patients in the present study. The PT and APTT were significantly longer in those who died, but there was no difference with TT. The incidences of PT and APTT prolongation were also increased in those who died. PT and APTT evaluate the integrity of the extrinsic and intrinsic pathways of coagulation, respectively, while both PT and APTT are affected by the final common pathway[18,19]. The prolonged PT and APTT in those who died might indicate the activation of coagulation and the consumption of coagulation factors.

Elevation of D-dimer and FDP were found in 57.7% and 31% of the COVID-19 patients, respectively, which was consistent with previous reports[3,6]. The median concentrations of D-dimer and FDP were significantly increased in those who died compared with survivors. D-dimer and FDP both originate from the degradation of fibrin and are manifestations for thrombosis and the activation of the fibrinolysis system. Elevation of D-dimer was also associated with severe infection[15,20]. The raised D-dimer and FDP concentrations implicate thrombophilia and system inflammation in those COVID-19 patients.

As the platelet count and several parameters of coagulation were significantly different between those who died and survivors, the prognostic value of these factors for COVID-19 was analyzed using logistic regression. PT, concentrations of D-dimer and FDP, age and respiration rate were found to contribute to the fatal outcome in COVID-19 patients. Multivariate analysis showed that PT was a strong prognostic factor with an odds ratio of 2.190 in the COVID-19 patients. FDP concentration was also predictive for the clinical outcomes of COVID-19 patients; however, the prognostic value was limited as the odds ratio was around 1. Age and respiration rate were also found to be prognostic factors in the multivariate analysis, which probably reflect the baseline state and the degree of hypoxia. To further illustrate the impact of PT prolongation on the fatality, the patients were divided into prolonged PT group and normal PT group. Then the survival curve was plotted and analyzed using Kaplan-Meier analysis. The prolonged PT group showed significantly lower estimated survival rate at day 5 of hospitalization, at day 11 of hospitalization and at the end date of follow-up. These data demonstrated that prolonged PT at admission could be a warning sign for high risk of death in the COVID-19 patients.

Tang *et al*[21] reported the abnormal coagulation in COVID-19 patients. In their study, the comparison of coagulation parameters in survivors and those who died was based on a 10-d to 12-d observation. Significant anomalies of coagulation parameters were observed in those who died, and the development of DIC was more frequent in those who died. DIC is a serious abnormality of coagulation function that usually occurs at the late stage of infectious diseases. In our present study, there were only two patients with DIC (≥ 5 points)[22] at admission (data not shown). The occurrence of DIC reflects the severity of disease. However, it may not have great predictive value.

In our present study, coagulation parameters at admission were analyzed using multivariate logistic regression, which showed PT is a strong prognosis factors of COVID-19. The PT is a measure of the integrity of the extrinsic and final common pathways of the coagulation cascade that consists of tissue factor and factors VII, II, V, X and fibrinogen. The elevation of PT/international normalized ratio in infectious disease is usually accompanied with low factor levels of VII, IX and X. This is associated with bleeding risk and relates to thrombosis in the patients with infectious disease[23]. PT could be a relatively early and sensitive indicator for systematic coagulation dysfunction in infectious disease. Our study underscores the need for early detection of coagulation function, which is especially important for risk assessment in COVID-19 patients.

**CONCLUSION**

Coagulation disorders were significantly more common in the patients who died with COVID-19 than the survivors. Prothrombin time, concentration of fibrin degradation products, respiration rate and age were predictive factors for clinical outcomes of COVID-19 patients. Patients with prolonged prothrombin time at admission should be treated with caution as they were faced with much higher risk of death.

**ARTICLE HIGHLIGHTS**

***Research background***

Coronavirus disease 2019 (COVID-19) has been spreading rapidly around the world. The disease progressed extremely fast in some severe to critical patients.

***Research motivation***

Early identification of COVID-19 patients at high risk is important for improving the clinical practice and outcomes.

***Research objectives***

To investigate the abnormalities of coagulation parameters in the patients with COVID-19 and their prognostic values.

***Research methods***

A retrospective, single-center study included 213 patients. The coagulation parameters at admission were compared between the survivors and those who died. The prognostic values of coagulation disorders were analyzed with logistic regression.

***Research results***

Coagulation disorders were significantly more common in the patients who died with COVID-19 than the survivors. Prothrombin time (PT), concentration of fibrin degradation products, respiration rate and age were predictive factors for fatal outcomes. The fatality of patients with prolonged PT at admission was significantly higher than those with normal PT.

***Research conclusions***

Patients with prolonged PT at admission were faced with a much higher risk of death. Thus, clinicians should be aware of this and treat these patients with caution.

***Research perspectives***

Patients with prolonged prothrombin time at admission should be treated with caution as they faced a much higher risk of death. Coagulation disorders were significantly more common in the patients who died with COVID-19.

**REFERENCES**

1 **World Health Organization**. Coronavirus disease 2019 (COVID-19): Situation Report – 59. 2020. accessed 19 March 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200319-sitrep-59-covid-19.pdf?sfvrsn=c3dcdef9\_2

2 **Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention.** [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; **41**: 145-151 [PMID: 32064853 DOI: 10.3760/cma.j.issn.0254-6450.2020.02.003]

3 **Wang D**, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020 [PMID: 32031570 DOI: 10.1001/jama.2020.1585]

4 **Chen N**, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; **395**: 507-513 [PMID: 32007143 DOI: 10.1016/S0140-6736(20)30211-7]

5 **Han H**, Yang L, Liu R, Liu F, Wu KL, Li J, Liu XH, Zhu CL. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. *Clin Chem Lab Med* 2020; **58**: 1116-1120 [PMID: 32172226 DOI: 10.1515/cclm-2020-0188]

6 **Tao J,** Song Z, Yang L, Huang C, Feng A, Man X. Emergency management for preventing and controlling nosocomial infection of 2019 novel coronavirus: implications for the dermatology department. *Br J Dermatol* 2020; **182:** 1477-1478 [PMID: 321410582020 DOI:10.1111/bjd.19011]

7 **Guan WJ**, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; **382**: 1708-1720 [PMID: 32109013 DOI: 10.1056/NEJMoa2002032]

8 **National Health Commision of the People's Republic of China**. Interim guidance for novel coronavirus pneumonia (Trial Implementation of Sixth Edition). 2020. accessed 27 February 2020. Available from: <http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml>

9 **Sung SA**, Jo SK, Cho WY, Won NH, Kim HK. Reduction of renal fibrosis as a result of liposome encapsulated clodronate induced macrophage depletion after unilateral ureteral obstruction in rats. *Nephron Exp Nephrol* 2007; **105**: e1-e9 [PMID: 17106213 DOI: 10.1159/000096859]

10 **Singh SK**. Middle East Respiratory Syndrome Virus Pathogenesis. *Semin Respir Crit Care Med* 2016; **37**: 572-577 [PMID: 27486737 DOI: 10.1055/s-0036-1584796]

11 **Zumla A**, Hui DS, Perlman S. Middle East respiratory syndrome. *Lancet* 2015; **386**: 995-1007 [PMID: 26049252 DOI: 10.1016/S0140-6736(15)60454-8]

12 **Gralinski LE**, Bankhead A 3rd, Jeng S, Menachery VD, Proll S, Belisle SE, Matzke M, Webb-Robertson BJ, Luna ML, Shukla AK, Ferris MT, Bolles M, Chang J, Aicher L, Waters KM, Smith RD, Metz TO, Law GL, Katze MG, McWeeney S, Baric RS. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. *mBio* 2013; **4**: [PMID: 23919993 DOI: 10.1128/mBio.00271-13]

13 **Goeijenbier M**, van Gorp EC, Van den Brand JM, Stittelaar K, Bakhtiari K, Roelofs JJ, van Amerongen G, Kuiken T, Martina BE, Meijers JC, Osterhaus AD. Activation of coagulation and tissue fibrin deposition in experimental influenza in ferrets. *BMC Microbiol* 2014; **14**: 134 [PMID: 24884666 DOI: 10.1186/1471-2180-14-134]

14 **Goeijenbier M**, van Wissen M, van de Weg C, Jong E, Gerdes VE, Meijers JC, Brandjes DP, van Gorp EC. Review: Viral infections and mechanisms of thrombosis and bleeding. *J Med Virol* 2012; **84**: 1680-1696 [PMID: 22930518 DOI: 10.1002/jmv.23354]

15 **Levi M**, van der Poll T. Coagulation and sepsis. *Thromb Res* 2017; **149**: 38-44 [PMID: 27886531 DOI: 10.1016/j.thromres.2016.11.007]

16 **Wong RS**, Wu A, To KF, Lee N, Lam CW, Wong CK, Chan PK, Ng MH, Yu LM, Hui DS, Tam JS, Cheng G, Sung JJ. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. *BMJ* 2003; **326**: 1358-1362 [PMID: 12816821 DOI: 10.1136/bmj.326.7403.1358]

17 **Thachil J**, Warkentin TE. How do we approach thrombocytopenia in critically ill patients? *Br J Haematol* 2017; **177**: 27-38 [PMID: 27982413 DOI: 10.1111/bjh.14482]

18 **Chee YL**. Coagulation. *J R Coll Physicians Edinb* 2014; **44**: 42-45 [PMID: 24995447 DOI: 10.4997/JRCPE.2014.110]

19 **Yang R**, Moosavi L. Prothrombin Time. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 [PMID: 31334989]

20 **Fan SL**, Miller NS, Lee J, Remick DG. Diagnosing sepsis - The role of laboratory medicine. *Clin Chim Acta* 2016; **460**: 203-210 [PMID: 27387712 DOI: 10.1016/j.cca.2016.07.002]

21 **Tang N**, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost* 2020; **18**: 844-847 [PMID: 32073213 DOI: 10.1111/jth.14768]

22 **Taylor FB Jr**, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. *Thromb Haemost* 2001; **86**: 1327-1330 [PMID: 11816725]

23 **Walborn A**, Williams M, Fareed J, Hoppensteadt D. International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treatment and Disseminated Intravascular Coagulation. *Clin Appl Thromb Hemost* 2018; **24**: 1033-1041 [PMID: 29848060 DOI: 10.1177/1076029618772353]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the National Natural Science Foundation of China.

**Informed consent statement:** The National Natural Science Foundation of China waived the informed consent for this study.

**Conflict-of-interest statement:** There is no conflict of interests.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding Author’s Membership in Professional Societies:** Standing Committee Member of Chinese Society of Cardiology; and Fellow of the American College of Cardiology.

**Peer-review started:** April 28, 2020

**First decision:** May 21, 2020

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Pedrazzani C, Sung WW, Zhang J **S-Editor:** Zhang H **L-Editor:** Filipodia **P-Editor:**

**Figure Legends**

****

**Figure 1 Survival curves of patients with prolonged prothrombin time and normal prothrombin time.** The survival curves of patients with prolonged prothrombin time and normal prothrombin time were analyzed using Kaplan-Meier analysis. Log-rank, Breslow and Tarone-Ware tests showed the survival curves of the two groups had a highly significant difference (*P* < 0.001). PT: Prothrombin time.

**Table1 Baseline characteristics of patients enrolled**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristics** | **Total, *n* = 213** | **Survival, *n* = 178** | **Death, *n* = 35** | ***P* value, death *vs* survival** |
| Age in yr, median (IQR)  | 62 (51-69) | 60 (49-67) | 73 (65-84) | < 0.001 |
| Sex |  |  |  |  |
| Male  | 95 (44.6%) | 71 (39.9%) | 24 (68.6%) | 0.002 |
| Comorbidities |  |  |  |  |
| Hypertension | 59 (27.7%) | 44 (24.7%) | 15 (42.8%) | 0.028 |
| Diabetes | 22 (10.3%) | 18 (10.1%) | 4 (11.4%) | 0.815 |
| Cardiovascular disease | 17 (8.0%) | 12 (6.7%) | 5 (14.3%) | 0.132 |
| Cerebrovascular disease | 10 (4.7%) | 4 (2.2%) | 6 (17.1%) | < 0.001 |
| Chronic kidney disease | 9 (4.2%) | 5 (2.8%) | 4 (11.4%) | 0.02 |
| COPD | 10 (4.7%) | 4 (2.2%) | 6 (17.1%) | < 0.001 |
| Malignancy | 10 (4.7%) | 8 (4.5%) | 2 (5.7%) | 0.755 |
| Autoimmune disease | 4 (1.9%) | 3 (1.7%) | 1 (2.9%) | 0.641 |
| Vital signs at admission |  |  |  |  |
| Heart rate as bpm, median (IQR) | 85 (78-92) | 84 (76-91) | 86 (79-95) | 0.198 |
| SBP in mmHg, median (IQR) | 125 (116-135) | 125 (118-134) | 124 (110-143) | 0.535 |
| DBP in mmHg, median (IQR) | 76 (70-80) | 77 (70-80) | 74 (65-86) | 0.683 |
| Respiration rate times per min, median (IQR) | 20 (18-21) | 19 (18-20) | 23 (19-27) | < 0.001 |
| Spectrum |  |  |  |  |
| Moderate | 83 (39.0%) | 83 (46.6%) | 0 |  |
| Severe | 79 (37.1%) | 79 (44.4%) | 0 |  |
| Critical | 51 (23.9%) | 16 (9.0%) | 35 (100.0%) |  |
| Symptom onset to admission/d, median (IQR) | 10 (7-12) | 10 (7-12) | 10 (7-14) | 0.453 |
| Hospitalization stay in d, median (IQR) | 27 (14-35) | 32 (22-36) | 6 (4-8) | < 0.001 |

BPM: Beats per min; COPD: Chronic obstructive pulmonary disease; DBP: Diastolic blood pressure; IQR: Interquartile range; SBP: Systolic blood pressure.

**Table2 Laboratory findings at admission**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Normal Range** | **Total, *n* = 213** | **Survival, *n* = 178** | **Death, *n* = 35** | ***P* value, death *vs* survival** |
| Platelet count × 109/L, median (IQR) |  125-350 | 204 (152-255) | 211 (157-264) | 169 (117-208) | 0.002 |
| Blood coagulation |  |  |  |  |  |
| PT/s, median (IQR) |  9-13 | 12.1 (11.5-12.7) | 12 (11.5-12.6) | 12.9 (12.0-14.0) | < 0.001 |
| APTT/ s, median (IQR) |  25-31.3 | 28.8 (26.5-31.3) | 28.6 (26.2-31.2) | 29.8 (28.2-32.9) | 0.033 |
| TT/ s, median (IQR) |  14-21 | 17.3 (16.5-18.3) | 17.3 (16.4-18.2) | 17.6 (16.7-19.5) | 0.099 |
| Fibrinogen in g/L, median (IQR) |  2-4 | 4.10 (3.32-5.12) | 4.17 (3.39-5.12) | 3.94 (2.49-5.18) | 0.294 |
| D-dimer in mg/L, median (IQR) |  0-0.55 | 0.73 (0.40-1.95) | 0.62 (0.37-1.63) | 2.72 (0.91-17.45) | < 0.001 |
| FDP in mg/L, median (IQR) |  0-5 | 2.72 (1.05-7.05) | 2.10 (0.98-5.33) | 9.68 (3.20-90.68) | < 0.001 |
| Incidence of coagulation abnormalities |  |  |  |  |  |
| Thrombocytopenia |  | 26 (12.2%) | 17 (9.6%) | 9 (25.7%) | 0.02 |
| Thrombocytosis |  | 10 (4.7%) | 10 (5.6%) | 0 | 0.374 |
| PT prolongation |  | 39 (18.8%) | 23 (14.6%) | 16 (45.7%) | < 0.001 |
| APTT prolongation  |  | 56 (26.3%) | 41 (23.0%) | 15 (42.6) | 0.02 |
| APTT shortening |  | 27 (12.7%) | 25 (14.0%) | 2 (5.7%) | 0.265 |
| TT prolongation |  | 8 (3.8%) | 3 (1.7%) | 5 (14.2%) | 0.004 |
| Fibrinogen elevation |  | 105 (49.29%) | 89 (50%) | 16 (45.7%) | 0.708 |
| Fibrinogen reduction |  | 9 (4.7%) | 5 (2.8%) | 4 (11.4%) | 0.043 |
| D-dimer elevation |  | 123 (57.7%) | 92 (51.7%) | 31 (88.6%) | < 0.001 |
| FDP elevation |  | 66 (31.0%) | 47 (26.4%) | 19 (54.3%) | 0.002 |

APTT: Activated partial thromboplastin time; COPD: Chronic obstructive pulmonary disease; FDP: Fibrin degradation products; IQR: Interquartile range; PT: Prothrombin time; TT: Thrombin time.

**Table3 Univariate and multivariate logistic regression for prognosis factors**

|  |  |  |  |
| --- | --- | --- | --- |
| **Factors** | **OR** | **95%CI** | ***P* value** |
| Univariate analysis  |
| Age | 1.083  | 1.048-1.120 | < 0.001 |
| Male | 3.288  | 1.516-7.131 | 0.003 |
| Hypertension | 2.284  | 2.284-1.078 | 0.031 |
| Cerebrovascular disease | 9.000  | 2.393-33.854 | 0.001 |
| Chronic kidney disease | 4.465  | 1.135-17.556 | 0.032 |
| COPD | 9.000  | 2.393-33.854 | 0.001 |
| Respiration rate  | 1.192  | 1.098-1.293 | < 0.001 |
| PT | 2.734  | 1.778-4.202 | < 0.001 |
| D-dimer | 1.062  | 1.021-1.105 | 0.003 |
| FDP | 1.031  | 1.017-1.044 | < 0.001 |
| Multivariate analysis |
| Age | 1.074  | 1.034-1.115 | < 0.001 |
| RR | 1.223  | 1.095-1.366 | < 0.001 |
| PT | 2.190  | 1.285-3.733 | 0.004 |
| FDP | 1.020  | 1.004-1.037 | 0.014 |

CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; FDP: Fibrin degradation products; OR: Odds ratio; PT: Prothrombin time.